Mexiletine in treatment of ventricular arrhythmias. A long-term follow-up. 1979

L Stavenow, and A Hanson, and B W Johansson

Maxiletine, a new drug effective in the treatment of ventricular arrhythmias, was given to 20 patients for approximately 2 years. The study was designed to investigate the nature and prevalence of side-effects during long-term therapy, and the degree of correlation between such effects and the serum levels of the drug. The methodology used to determine the serum level is described. Mexiletine was well tolerated and serious side-effects were not seen. In particular, antinuclear factor was not detected during the treatment period. The serum level of mexiletine was easily maintained within the therapeutic range, and most side-effects correlated closely with the drug level. Mexiletine appears to be an effective alternative to currently available antiarrhythmic agents.

UI MeSH Term Description Entries
D008297 Male Males
D008801 Mexiletine Antiarrhythmic agent pharmacologically similar to LIDOCAINE. It may have some anticonvulsant properties. KO-1173,KO1173,KOE-1173,Mexiletene,Mexiletine Hydrochloride,Mexitil,Mexitil PL,Mexityl,Novo-Mexiletine,KO 1173,KOE 1173,KOE1173,Novo Mexiletine
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D011437 Propylamines Derivatives of propylamine (the structural formula NH2CH2CH2CH3).
D002849 Chromatography, Gas Fractionation of a vaporized sample as a consequence of partition between a mobile gaseous phase and a stationary phase held in a column. Two types are gas-solid chromatography, where the fixed phase is a solid, and gas-liquid, in which the stationary phase is a nonvolatile liquid supported on an inert solid matrix. Chromatography, Gas-Liquid,Gas Chromatography,Chromatographies, Gas,Chromatographies, Gas-Liquid,Chromatography, Gas Liquid,Gas Chromatographies,Gas-Liquid Chromatographies,Gas-Liquid Chromatography
D004341 Drug Evaluation Any process by which toxicity, metabolism, absorption, elimination, preferred route of administration, safe dosage range, etc., for a drug or group of drugs is determined through clinical assessment in humans or veterinary animals. Evaluation Studies, Drug,Drug Evaluation Studies,Drug Evaluation Study,Drug Evaluations,Evaluation Study, Drug,Evaluation, Drug,Evaluations, Drug,Studies, Drug Evaluation,Study, Drug Evaluation
D005260 Female Females
D005500 Follow-Up Studies Studies in which individuals or populations are followed to assess the outcome of exposures, procedures, or effects of a characteristic, e.g., occurrence of disease. Followup Studies,Follow Up Studies,Follow-Up Study,Followup Study,Studies, Follow-Up,Studies, Followup,Study, Follow-Up,Study, Followup
D006207 Half-Life The time it takes for a substance (drug, radioactive nuclide, or other) to lose half of its pharmacologic, physiologic, or radiologic activity. Halflife,Half Life,Half-Lifes,Halflifes
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man

Related Publications

L Stavenow, and A Hanson, and B W Johansson
January 1977, Postgraduate medical journal,
L Stavenow, and A Hanson, and B W Johansson
January 1976, American heart journal,
L Stavenow, and A Hanson, and B W Johansson
January 1978, The Journal of the Kansas Medical Society,
L Stavenow, and A Hanson, and B W Johansson
October 1995, Japanese circulation journal,
L Stavenow, and A Hanson, and B W Johansson
May 1982, Zeitschrift fur die gesamte innere Medizin und ihre Grenzgebiete,
L Stavenow, and A Hanson, and B W Johansson
March 1986, Kokyu to junkan. Respiration & circulation,
L Stavenow, and A Hanson, and B W Johansson
January 1980, Acta cardiologica. Supplementum,
L Stavenow, and A Hanson, and B W Johansson
December 1996, Circulation,
L Stavenow, and A Hanson, and B W Johansson
April 1981, The American journal of cardiology,
L Stavenow, and A Hanson, and B W Johansson
October 1976, Drug and therapeutics bulletin,
Copied contents to your clipboard!